Rebastinib

Target: Rebastinib targets ABL1/BCR-ABL, including T315I, and also inhibits SRC, KDR, FLT3, and Tie-2.

Mechanism of Action: Rebastinib can act as a kinase-recognition ligand for PROTAC strategies involving ABL1/BCR-ABL or other validated rebastinib-sensitive kinases. In a degrader, the rebastinib-derived warhead binds the target kinase, while the linker connects it to an E3 ligase ligand. The design objective is to generate a ternary complex in which the bound kinase is positioned near the recruited ligase. If the complex supports ubiquitin transfer, the kinase is polyubiquitinated and eliminated by the proteasome, converting target engagement into protein depletion. This establishes a testable protein-depletion mechanism for research assays.

• PROTAC-Mediated Kinase Degradation: Rebastinib can serve as a kinase-binding ligand within PROTAC architectures to recruit an E3 ligase and drive ubiquitin-dependent degradation of its target protein. This enables systematic interrogation of kinase function by comparing degradation-dependent phenotypes with inhibition-only controls in cellular and biochemical assays.

• E3 Ligase Recruitment Optimization: Incorporating Rebastinib into PROTAC designs allows researchers to test multiple E3 ligase recruiters and linker geometries to maximize ternary complex formation. By tuning spatial orientation and residence time, investigators can enhance degradation efficiency while minimizing off-target ubiquitination and non-specific proteome effects.

• Mechanism-of-Action Profiling: Rebastinib-based PROTACs support rigorous mechanistic studies distinguishing catalytic inhibition from degradation-driven signaling rewiring. Using proteasome inhibition, competition with free ligand, and time-course immunoblotting, researchers can quantify degradation kinetics, assess pathway dependencies, and map downstream transcriptional and phenotypic outcomes.

• Target Selectivity and Resistance Studies: Rebastinib PROTACs can be used to evaluate selectivity across related kinase family members by monitoring degradation breadth in proteomic or panel-based assays. Additionally, comparing degradation profiles across mutant or drug-resistant backgrounds helps determine whether resistance mechanisms impair ligand binding, ternary complex stability, or ubiquitination efficiency.

Rebastinib is an ABL/TIE2-associated kinase inhibitor with a multi-heteroaryl urea-carboxamide scaffold suitable for target-ligand exploration in degrader programs. Its fluorophenoxy, quinolinyl-pyrazolyl, and N-methylpyridine carboxamide components offer several SAR-dependent linker-vector possibilities. This molecule is described in detail below.

Structure: The molecule contains a tert-butyl quinolinyl pyrazole urea motif connected through a fluorophenoxy linker to an N-methylpyridine carboxamide. This extended aromatic framework combines multiple hydrogen-bonding sites with hydrophobic substituents.

Reactivity: For ABL or TIE2 degrader design, linker growth should be guided by kinase co-structures or analogue SAR, because the urea, pyrazole, and pyridine carboxamide may each participate in binding. PEG, alkyl, or aryl-ether-compatible linkers may be paired with CRBN, VHL, IAP, or MDM2 ligands, but the high aromatic content argues for careful control of linker lipophilicity and molecular size.